Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism
about
Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4Importance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro dataEvaluation of the pharmacokinetic interaction between lesogaberan (AZD3355) and esomeprazole in healthy subjects.Effect of clopidogrel on the hydroxylation and sulfoxidation of omeprazole: A single dose study in healthy human volunteers.Review article: cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole.Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors.Prediction of relative in vivo metabolite exposure from in vitro data using two model drugs: dextromethorphan and omeprazole.Selection of drugs to treat gastro-oesophageal reflux disease: the role of drug interactions.Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism.Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms.In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by S-mephenytoin hydroxylase.Interphenotype differences in disposition and effect on gastrin levels of omeprazole--suitability of omeprazole as a probe for CYP2C19Pharmacogenetics of the proton pump inhibitors: a systematic review.Pharmacokinetic drug interaction profiles of proton pump inhibitors.BJCP 40th anniversary: moving forward, looking back.Cytochromes P450 and species differences in xenobiotic metabolism and activation of carcinogen.Evolution of drug metabolism: hitchhiking the technology bandwagon.Genetic polymorphisms of cytochrome P450 enzymes and the effect on interindividual, pharmacokinetic variability in extensive metabolizers.The effect of ethinyloestradiol and levonorgestrel on the CYP2C19-mediated metabolism of omeprazole in healthy female subjectsLiver-stage malaria parasites vulnerable to diverse chemical scaffolds.Reliability of the omeprazole hydroxylation index for CYP2C19 phenotyping: possible effect of age, liver disease and length of therapy.Comparison of (S)-mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms.Formation of omeprazole sulphone but not 5-hydroxyomeprazole is inhibited by grapefruit juice.The effect of omeprazole and esomeprazole on the maintenance dose of phenprocoumonIncreased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers.Induction of CYP2C19 and CYP3A activity following repeated administration of efavirenz in healthy volunteers.Population pharmacokinetics of omeprazole in a random Iranian population.Stereoselective disposition of proton pump inhibitors.PhRMA white paper on ADME pharmacogenomics.Inhibition and induction of human cytochrome P450 enzymes: current status.Effects of water deprivation on drug pharmacokinetics: correlation between drug metabolism and hepatic CYP isozymes.Effect of fermented red ginseng on cytochrome P450 and P-glycoprotein activity in healthy subjects, as evaluated using the cocktail approach.Drug-drug interaction profiles of proton pump inhibitors.Azole interactions with multidrug therapy in pediatric oncology.The expression levels of CYP3A4 and CYP3A5 serve as potential prognostic biomarkers in lung adenocarcinoma.Which has superior acid-suppressive effect, 10 mg omeprazole once daily or 20 mg famotidine twice daily? Effects of single or repeated administration in Japanese Helicobacter pylori-negative CYP2C19 extensive metabolizers.Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects.Overview of enzymes of drug metabolism.Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions.Investigation of clinical interaction between omeprazole and tacrolimus in CYP3A5 non-expressors, renal transplant recipients.
P2860
Q24564971-2E0349D0-027B-416C-B2D6-8225D34A8ACFQ27009128-A6890272-2135-4E21-8959-0E58504959F7Q33448993-28B2768C-E1FD-4DD1-92AE-2F27486B3570Q33667262-32262A4B-1516-47C3-80E4-446C3DD7DA53Q33734852-56A14149-E8A7-469A-B7C7-6D1F9EDDC2CDQ33912651-CC778AB7-C46F-49D6-BE03-5CB78CE8CC39Q34051253-4E687BAF-C8D2-4A71-A82B-92078B293AF6Q34078487-35F9F242-5D5B-4B83-B5EA-1222C8F689A0Q34346434-D8E80EA8-36CC-44D5-8BE8-4178D8922293Q34346567-F5F41DB9-1A05-421D-87AA-8848968AB16CQ34346652-55A7270C-DC4C-41FB-B40D-F8671AD70081Q34347232-97779A46-F7DA-49C7-B046-10BEF55F1923Q34532600-0E0554F9-F90F-4C06-99F2-8B7FFC72E264Q34570478-DDDE7AA1-837F-43C5-88AF-2FDCEBFE10C4Q34635476-E2E405E1-7B13-4B52-A1EF-813C39988C17Q34939015-89088C16-A6A1-4C26-83BC-DCF1CEFF38B6Q34941200-4A48D277-0FC7-476E-A7E3-ABD1DD6FBC5FQ35753607-98A39ECA-1536-46C2-BCEB-5C1CE6320C2AQ35825470-2B8FD96D-1E5E-4A9B-8CFE-F7C2A0B65286Q36001246-392B917D-739E-45B1-A82C-22431F2C0621Q36053279-40F073AE-8BAA-4D1D-BBE0-62B38F037C8BQ36053568-BE5102C9-61CD-4493-BC37-4BA1B45374E8Q36055042-37004095-32AE-476D-A073-3B3DBCECC751Q36468182-8E647F0D-11BB-4CB9-A2B4-13B1047BEAF7Q36729190-8E9C82DA-9699-4452-8A1D-B893DA7368D0Q36887128-E572EC64-EFC0-4349-8A0E-7306E6CDE451Q37128495-FDE0F339-20D1-42B8-B39A-B4210C18F004Q37136970-F9AA12F5-7EA0-45A9-B5E3-3539EE873EECQ37182212-5C0D4FCF-2403-4AA5-BE8E-218A8929C1A8Q37212794-CDC364C3-9B07-4360-8445-CDAF7CF1907DQ37267276-23FE3F3F-EF7B-4C57-B6CB-E10E0E862238Q37399585-7DCEB54D-F5F2-4DE2-A95C-8DD8AE4A9BA0Q37770556-F0D87632-ADC9-4688-8A50-582FF77AF70EQ38015710-56FF94AE-68BD-46F3-8297-40F5A5A15F30Q38851906-2A3CECCB-9CF2-4171-B55F-7F97472F6CCFQ39341299-8B9B3737-CE27-4809-A533-DFDE7BB3C5EDQ40885346-0FC51508-B249-4EE2-BA33-B78FA74D386AQ41456093-04F63B6F-6299-42F1-83F3-D3CEB9FC9BE2Q41482802-2A535A3E-0A3D-42A6-916A-802AC8349868Q41532194-F29D211F-D8E8-4149-A047-B4E27F5A8388
P2860
Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism
description
1993 nî lūn-bûn
@nan
1993 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism
@ast
Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism
@en
Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism
@nl
type
label
Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism
@ast
Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism
@en
Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism
@nl
prefLabel
Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism
@ast
Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism
@en
Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism
@nl
P2093
P2860
P1476
Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism
@en
P2093
Andersson T
Birkett DJ
Tassaneeyakul W
Veronese ME
P2860
P304
P356
10.1111/J.1365-2125.1993.TB00410.X
P407
P577
1993-12-01T00:00:00Z